Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy

Qi Gao(Memorial Sloan Kettering Cancer Center), Mikhail Roshal(Memorial Sloan Kettering Cancer Center)

Cytometry Part B Clinical Cytometry

March 30, 2023

10.1002/cyto.b.22120

Cited by 16

Related Papers

GPRC5D-Targeted CAR T Cells for Myeloma

|New England Journal of Medicine|2022|383

Activation of the ATR-mediated DNA Damage Response by the HIV-1 Viral Protein R

|Journal of Biological Chemistry|2003|200

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

|JAMA Oncology|2021|119

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

|Blood|2018|100

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

|The Lancet Haematology|2021|95